Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial
Abstract The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial compri...
Gespeichert in:
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.) Fla.), 2015-10, Vol.160 (2), p.349-357 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 357 |
|---|---|
| container_issue | 2 |
| container_start_page | 349 |
| container_title | Clinical immunology (Orlando, Fla.) |
| container_volume | 160 |
| creator | Esmaeilzadeh, Hossein Nabavi, Mohammad Aryan, Zahra Arshi, Saba Bemanian, Mohammad Hassan Fallahpour, Morteza Mortazavi, Negar |
| description | Abstract The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial comprised 34 adult patients (67.6% female) with chronic rhinosinusitis, nasal polyps, and aspirin-intolerant asthma. The active group underwent AD over a 2-day period with increasing doses of aspirin (60, 125, 325, and 625 mg), followed by receiving aspirin 625 mg twice daily for 6 months. Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months (7.5 ± 3.5 vs. 10.6 ± 3.8 and 9.3 ± 2.0 vs. 11.0 ± 3.1, respectively, all p < 0.05). However, no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study. |
| doi_str_mv | 10.1016/j.clim.2015.05.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751207495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521661615001862</els_id><sourcerecordid>1751207495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-ee0abbf34dab35adc16df04f86806648274e8c3b5c7ca4792e5c61d11a35099d3</originalsourceid><addsrcrecordid>eNqNkk-r1TAQxYsovufTL-BCunTTayZN0lZEuDz8Bw9cqOuQJlPMNU1qkqr37f3eptyrCxciDGSY_M5ZzJmqegxkBwTEs8NOOzvvKAG-I6WA3qkugVNoOtLyu-deCBAX1YOUDoQQTqm4X11QQfp2YP1l9XOfFhutrw0m9Mlme6uyDb6eQqyX0qLPqf5u8-dancgGfyiNcVQZTR1xG6oc4rE2NqFK-Lze11F5E2Z7WwgT1tFhMzrrTb24Ih1Do4PPMThX_nO0yj2s7k3KJXx0fq-qT69ffbx-29y8f_Puen_TaMZYbhCJGsepZUaNLVdGgzATYVMveiIE62nHsNftyHWnFesGilwLMACq5WQYTHtVPT35LjF8XTFlOduk0TnlMaxJQseBko4N_D9QEEPLCOsLSk-ojiGliJNcop1VPEogcktKHuSWlNySkqQU0CJ6cvZfxxnNH8nvaArw4gRgWcg3i1EmXdLQaGxEnaUJ9t_-L_-SF8RbrdwXPGI6hDX6smoJMlFJ5IftVrZTAU4I9IK2vwACDbyT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1716934048</pqid></control><display><type>article</type><title>Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Esmaeilzadeh, Hossein ; Nabavi, Mohammad ; Aryan, Zahra ; Arshi, Saba ; Bemanian, Mohammad Hassan ; Fallahpour, Morteza ; Mortazavi, Negar</creator><creatorcontrib>Esmaeilzadeh, Hossein ; Nabavi, Mohammad ; Aryan, Zahra ; Arshi, Saba ; Bemanian, Mohammad Hassan ; Fallahpour, Morteza ; Mortazavi, Negar</creatorcontrib><description>Abstract The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial comprised 34 adult patients (67.6% female) with chronic rhinosinusitis, nasal polyps, and aspirin-intolerant asthma. The active group underwent AD over a 2-day period with increasing doses of aspirin (60, 125, 325, and 625 mg), followed by receiving aspirin 625 mg twice daily for 6 months. Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months (7.5 ± 3.5 vs. 10.6 ± 3.8 and 9.3 ± 2.0 vs. 11.0 ± 3.1, respectively, all p < 0.05). However, no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>DOI: 10.1016/j.clim.2015.05.012</identifier><identifier>PMID: 26083948</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Allergy and Immunology ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Aspirin - administration & dosage ; Aspirin - adverse effects ; Aspirin-intolerant asthma ; Asthma, Aspirin-Induced - drug therapy ; Asthma, Aspirin-Induced - etiology ; Asthma, Aspirin-Induced - immunology ; Desensitization ; Desensitization, Immunologic - methods ; Double-Blind Method ; Female ; Humans ; Interferon-gamma ; Interferon-gamma - immunology ; Interleukin-10 ; Interleukin-10 - immunology ; Male ; Nasal Polyps - drug therapy ; Nasal Polyps - immunology ; Quality of life ; Rhinitis - drug therapy ; Rhinitis - immunology ; Sinusitis - drug therapy ; Sinusitis - immunology ; Transforming Growth Factor beta - immunology ; Treatment Outcome ; Young Adult</subject><ispartof>Clinical immunology (Orlando, Fla.), 2015-10, Vol.160 (2), p.349-357</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-ee0abbf34dab35adc16df04f86806648274e8c3b5c7ca4792e5c61d11a35099d3</citedby><cites>FETCH-LOGICAL-c444t-ee0abbf34dab35adc16df04f86806648274e8c3b5c7ca4792e5c61d11a35099d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clim.2015.05.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26083948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Esmaeilzadeh, Hossein</creatorcontrib><creatorcontrib>Nabavi, Mohammad</creatorcontrib><creatorcontrib>Aryan, Zahra</creatorcontrib><creatorcontrib>Arshi, Saba</creatorcontrib><creatorcontrib>Bemanian, Mohammad Hassan</creatorcontrib><creatorcontrib>Fallahpour, Morteza</creatorcontrib><creatorcontrib>Mortazavi, Negar</creatorcontrib><title>Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial</title><title>Clinical immunology (Orlando, Fla.)</title><addtitle>Clin Immunol</addtitle><description>Abstract The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial comprised 34 adult patients (67.6% female) with chronic rhinosinusitis, nasal polyps, and aspirin-intolerant asthma. The active group underwent AD over a 2-day period with increasing doses of aspirin (60, 125, 325, and 625 mg), followed by receiving aspirin 625 mg twice daily for 6 months. Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months (7.5 ± 3.5 vs. 10.6 ± 3.8 and 9.3 ± 2.0 vs. 11.0 ± 3.1, respectively, all p < 0.05). However, no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study.</description><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - adverse effects</subject><subject>Aspirin-intolerant asthma</subject><subject>Asthma, Aspirin-Induced - drug therapy</subject><subject>Asthma, Aspirin-Induced - etiology</subject><subject>Asthma, Aspirin-Induced - immunology</subject><subject>Desensitization</subject><subject>Desensitization, Immunologic - methods</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Interferon-gamma</subject><subject>Interferon-gamma - immunology</subject><subject>Interleukin-10</subject><subject>Interleukin-10 - immunology</subject><subject>Male</subject><subject>Nasal Polyps - drug therapy</subject><subject>Nasal Polyps - immunology</subject><subject>Quality of life</subject><subject>Rhinitis - drug therapy</subject><subject>Rhinitis - immunology</subject><subject>Sinusitis - drug therapy</subject><subject>Sinusitis - immunology</subject><subject>Transforming Growth Factor beta - immunology</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1521-6616</issn><issn>1521-7035</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk-r1TAQxYsovufTL-BCunTTayZN0lZEuDz8Bw9cqOuQJlPMNU1qkqr37f3eptyrCxciDGSY_M5ZzJmqegxkBwTEs8NOOzvvKAG-I6WA3qkugVNoOtLyu-deCBAX1YOUDoQQTqm4X11QQfp2YP1l9XOfFhutrw0m9Mlme6uyDb6eQqyX0qLPqf5u8-dancgGfyiNcVQZTR1xG6oc4rE2NqFK-Lze11F5E2Z7WwgT1tFhMzrrTb24Ih1Do4PPMThX_nO0yj2s7k3KJXx0fq-qT69ffbx-29y8f_Puen_TaMZYbhCJGsepZUaNLVdGgzATYVMveiIE62nHsNftyHWnFesGilwLMACq5WQYTHtVPT35LjF8XTFlOduk0TnlMaxJQseBko4N_D9QEEPLCOsLSk-ojiGliJNcop1VPEogcktKHuSWlNySkqQU0CJ6cvZfxxnNH8nvaArw4gRgWcg3i1EmXdLQaGxEnaUJ9t_-L_-SF8RbrdwXPGI6hDX6smoJMlFJ5IftVrZTAU4I9IK2vwACDbyT</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Esmaeilzadeh, Hossein</creator><creator>Nabavi, Mohammad</creator><creator>Aryan, Zahra</creator><creator>Arshi, Saba</creator><creator>Bemanian, Mohammad Hassan</creator><creator>Fallahpour, Morteza</creator><creator>Mortazavi, Negar</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20151001</creationdate><title>Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial</title><author>Esmaeilzadeh, Hossein ; Nabavi, Mohammad ; Aryan, Zahra ; Arshi, Saba ; Bemanian, Mohammad Hassan ; Fallahpour, Morteza ; Mortazavi, Negar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-ee0abbf34dab35adc16df04f86806648274e8c3b5c7ca4792e5c61d11a35099d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - adverse effects</topic><topic>Aspirin-intolerant asthma</topic><topic>Asthma, Aspirin-Induced - drug therapy</topic><topic>Asthma, Aspirin-Induced - etiology</topic><topic>Asthma, Aspirin-Induced - immunology</topic><topic>Desensitization</topic><topic>Desensitization, Immunologic - methods</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Interferon-gamma</topic><topic>Interferon-gamma - immunology</topic><topic>Interleukin-10</topic><topic>Interleukin-10 - immunology</topic><topic>Male</topic><topic>Nasal Polyps - drug therapy</topic><topic>Nasal Polyps - immunology</topic><topic>Quality of life</topic><topic>Rhinitis - drug therapy</topic><topic>Rhinitis - immunology</topic><topic>Sinusitis - drug therapy</topic><topic>Sinusitis - immunology</topic><topic>Transforming Growth Factor beta - immunology</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Esmaeilzadeh, Hossein</creatorcontrib><creatorcontrib>Nabavi, Mohammad</creatorcontrib><creatorcontrib>Aryan, Zahra</creatorcontrib><creatorcontrib>Arshi, Saba</creatorcontrib><creatorcontrib>Bemanian, Mohammad Hassan</creatorcontrib><creatorcontrib>Fallahpour, Morteza</creatorcontrib><creatorcontrib>Mortazavi, Negar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical immunology (Orlando, Fla.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Esmaeilzadeh, Hossein</au><au>Nabavi, Mohammad</au><au>Aryan, Zahra</au><au>Arshi, Saba</au><au>Bemanian, Mohammad Hassan</au><au>Fallahpour, Morteza</au><au>Mortazavi, Negar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial</atitle><jtitle>Clinical immunology (Orlando, Fla.)</jtitle><addtitle>Clin Immunol</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>160</volume><issue>2</issue><spage>349</spage><epage>357</epage><pages>349-357</pages><issn>1521-6616</issn><eissn>1521-7035</eissn><abstract>Abstract The effect of aspirin desensitization (AD) on immunologic profile of patients with AERD has been poorly understood. This study is aimed at investigating the effect of AD on clinical and immunological markers of patients with AERD. This randomized double-blind placebo-controlled trial comprised 34 adult patients (67.6% female) with chronic rhinosinusitis, nasal polyps, and aspirin-intolerant asthma. The active group underwent AD over a 2-day period with increasing doses of aspirin (60, 125, 325, and 625 mg), followed by receiving aspirin 625 mg twice daily for 6 months. Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months (7.5 ± 3.5 vs. 10.6 ± 3.8 and 9.3 ± 2.0 vs. 11.0 ± 3.1, respectively, all p < 0.05). However, no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26083948</pmid><doi>10.1016/j.clim.2015.05.012</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6616 |
| ispartof | Clinical immunology (Orlando, Fla.), 2015-10, Vol.160 (2), p.349-357 |
| issn | 1521-6616 1521-7035 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1751207495 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Allergy and Immunology Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Aspirin - administration & dosage Aspirin - adverse effects Aspirin-intolerant asthma Asthma, Aspirin-Induced - drug therapy Asthma, Aspirin-Induced - etiology Asthma, Aspirin-Induced - immunology Desensitization Desensitization, Immunologic - methods Double-Blind Method Female Humans Interferon-gamma Interferon-gamma - immunology Interleukin-10 Interleukin-10 - immunology Male Nasal Polyps - drug therapy Nasal Polyps - immunology Quality of life Rhinitis - drug therapy Rhinitis - immunology Sinusitis - drug therapy Sinusitis - immunology Transforming Growth Factor beta - immunology Treatment Outcome Young Adult |
| title | Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A43%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aspirin%20desensitization%20for%20patients%20with%20aspirin-exacerbated%20respiratory%20disease:%20A%20randomized%20double-blind%20placebo-controlled%20trial&rft.jtitle=Clinical%20immunology%20(Orlando,%20Fla.)&rft.au=Esmaeilzadeh,%20Hossein&rft.date=2015-10-01&rft.volume=160&rft.issue=2&rft.spage=349&rft.epage=357&rft.pages=349-357&rft.issn=1521-6616&rft.eissn=1521-7035&rft_id=info:doi/10.1016/j.clim.2015.05.012&rft_dat=%3Cproquest_cross%3E1751207495%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1716934048&rft_id=info:pmid/26083948&rft_els_id=S1521661615001862&rfr_iscdi=true |